key: cord-0763927-jhmphkzi
authors: Shin, Sun Hye; Hong, Jun Ki; Hong, Soon Auck; Li, Kapsok; Yoo, Kwang Ho
title: Pityriasis rosea shortly after mRNA-1273 COVID-19 vaccination
date: 2021-11-02
journal: Int J Infect Dis
DOI: 10.1016/j.ijid.2021.10.055
sha: c73e5d69c10ce2062661f5fb7b886b74fb03fb73
doc_id: 763927
cord_uid: jhmphkzi

nan

With the increase in the rates of vaccination against COVID-19, various cutaneous reactions have been reported after vaccination including pityriasis rosea (PR) (Catala et al., 2021 , Johansen et al., 2021 , Marcantonio-Santa Cruz et al., 2021 , McMahon et al., 2021 . They are easy to overlook because the incidence of PR as a side effect of COVID-19 vaccination is extremely low, accounting for about 0.96 % of all cutaneous reactions (McMahon et al., 2021) .

A 29-year-old man presented with a herald patch on his right chest 2 hours after the second dose of mRNA-1273 COVID-19 vaccination ( Figure 1A ). Within 2 to 3 days, multiple skin lesions rapidly disseminated to the upper trunk and extremities ( Figure 1B ). He had no other systemic symptoms, and no previous history of COVID-19 infection. Skin biopsy showed focal parakeratosis, spongiosis, and superficial perivascular inflammatory infiltrates ( Figure   1C ). He was diagnosed with PR basing on the clinical and histological features.

According to Ogata et al. (Ogata et al., 2021) , the SARS-CoV-2 viral spike protein antigen was detected as early as day one post-vaccination, and peak levels were detected after an average of five days. Based on the literature, the time lapse between COVID-19 vaccination and the skin lesions ranged from 5 to 17 days, with an average of 12.7 days. However, our patient developed PR after only 2 hours receiving the vaccination in a very short interval.

This does not allow us to conclude that a true causal link exists between PR and vaccination in this case. This is because a short interval of 2 hours may not be sufficient for the vaccine to circulate throughout the bloodstream and induce an appropriate immune response.

However, in our patient, the skin lesions occurred after the second dose of the vaccination, and it is possible that PR may occur sooner in such a case than after the first dose of the vaccination. Johnston et al. (Johnston et al., 2021) recently reported that delayed localized cutaneous reactions may occur sooner after the second administration of the vaccine.

Moreover, previous history of PR is not generally related to recurrence or onset of the lesion, and is not an important consideration for this patient because there is no history of PR. Therefore, in the future, researchers should study the onset duration of the cutaneous reactions that occur following the administration of the first and second doses of the COVID-19 vaccine.

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper (C) Histopathologic examination shows patchy parakeratosis, mild spongiosis, and perivascular lymphocytic infiltration. (Hematoxylin and Eosin, original magnification ×100).

Cutaneous reactions after SARS-COV-2 vaccination: A cross-sectional Spanish nationwide study of 405 cases

Pityriasis rosea in otherwise asymptomatic confirmed COVID-19-positive patients: A report of 2 cases

Delayed Localized Hypersensitivity Reactions to the Moderna COVID-19 Vaccine: A Case Series

Pityriasis rosea developing after COVID-19 vaccination

Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: A registry-based study of 414 cases

Vaccine Antigen Detected in the Plasma of mRNA-1273 Vaccine Recipients